Navigation Links
Gilead Announces Presentation of Long-Term Data for Ambrisentan, a,Potential Treatment for Patients With Pulmonary Arterial,Hypertension

SAN FRANCISCO--(BUSINESS WIRE)--May 21, 2007 - Gilead Sciences, Inc. (Nasdaq:GILD) today announced results of two long-term studies evaluating ambrisentan, an investigational endothelin receptor antagonist (ERA) for the treatment of patients with pulmonary arterial hypertension (PAH). These long-term data are from patients who originally participated in the two pivotal Phase III ARIES studies and AMB-222, a Phase II study of patients who had previously discontinued other ERAs because of liver function abnormalities. These studies were selected for oral presentation at ATS 2007, the International Conference of the American Thoracic Society, taking place in San Francisco, California, May 18-23.

"Pulmonary arterial hypertension is a progressive, life-threatening disease for which new therapies are clearly needed," said Ronald J. Oudiz, MD, Associate Professor of Medicine, UCLA School of Medicine and Director, Liu Center for Pulmonary Hypertension, Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center. "The long-term clinical profile observed in these ambrisentan studies is very encouraging."

About the Studies

In the first presentation (Abstract #2307), Dr. Oudiz presented results from an integrated analysis of an ongoing, long-term extension study (ARIES-E) involving patients from the two 12-week Phase III placebo-controlled studies (ARIES-1 and ARIES-2). A total of 383 patients with idiopathic PAH or PAH associated with connective tissue disease, HIV infection, or anorexigen use who received at least one dose of ambrisentan (2.5, 5 or 10 mg once-daily) in ARIES-1, ARIES-2 or ARIES-E were included in the integrated analysis, which reflect data available as of February 2006 (mean exposure = 39 weeks; maximum exposure = 109 weeks).

Improvements in the non placebo-corrected 6-minute walk distance observed during the first 12 weeks of ambrisentan treatment (+37.7 meters) were sus
'"/>




Page: 1 2 3 4 5 6

Related medicine technology :

1. Second Phase III Study Evaluating Gileads Viread for the Treatment of Chronic Hepatitis B Virus Meets Primary Endpoint
2. Second Phase III Study Evaluating Gileads Viread for the Treatment of Chronic Hepatitis B Virus Meets Primary Endpoint
3. Phase III Study Evaluating Gileads Viread for the Treatment of Chronic Hepatitis B Virus Meets Primary Endpoint
4. Gilead Announces Achievement of Primary Efficacy Endpoint in Second Phase III Study of Aztreonam Lysine for Inhalation in Patients With Cystic Fibrosis
5. Gilead Announces Presentation of Positive Phase III Data on Aztreonam Lysine for Inhalation in Patients With Cystic Fibrosis
6. Data from Preclinical Studies of Gilead Nucleotide Compound GS 9219 to be Presented at AACR
7. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
8. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
9. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
10. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
11. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
Post Your Comments:
(Date:9/19/2014)... Conn. , Sept. 19, 2014 UBM ... , a leading online community to help oncologists and ... information available regarding the use of targeted therapies and ... cancer research and treatment.  Every September, ... a way to raise awareness about blood cancers—helping to ...
(Date:9/19/2014)... 19, 2014  Alere Inc. (NYSE: ALR ... following statement today in support of President Barack ... "As the global leader in rapid diagnostics for infectious ... strategy to address the serious threat of antibiotic resistance. ... Administration on initiatives to promote the development of rapid ...
(Date:9/19/2014)... ORLANDO, Fla. , Sept. 19, 2014 /PRNewswire/ ... to grow, with the publication of two papers this ... Otolaryngology – Head and Neck Surgery , ... both objective and subjective measures of sleep disordered breathing, ... for the reduction in obstructive sleep apnea severity and ...
Breaking Medicine Technology:OncoTherapy Network Highlights National Blood Cancer Awareness Month 2OncoTherapy Network Highlights National Blood Cancer Awareness Month 3OncoTherapy Network Highlights National Blood Cancer Awareness Month 4Alere Applauds President's Executive Order Combating Antibiotic-Resistant Bacteria 2New Data shows Reductions in obstructive sleep apnea (OSA) severity and improvement of quality of life with Inspire therapy 2New Data shows Reductions in obstructive sleep apnea (OSA) severity and improvement of quality of life with Inspire therapy 3New Data shows Reductions in obstructive sleep apnea (OSA) severity and improvement of quality of life with Inspire therapy 4
... 14, 2011 WaferGen Biosystems, Inc. (OTC Bulletin Board: ... systems, today reported financial results for the three months and ... revenue growth in 2010 to a total of $2.2 million ... $1.5 to $2 million for the year," said Alnoor Shivji, ...
... Inc. (Nasdaq: BNVI ) announced today that it will ... ended December 31, 2010 on Tuesday, March 15, 2011. The Company ... results on Tuesday, March 15, 2011, at 5:30 p.m. ET. ... can listen via a live audio only webcast, which can be ...
Cached Medicine Technology:WaferGen Reports Fourth Quarter and Full Year 2010 Financial Results 2WaferGen Reports Fourth Quarter and Full Year 2010 Financial Results 3WaferGen Reports Fourth Quarter and Full Year 2010 Financial Results 4WaferGen Reports Fourth Quarter and Full Year 2010 Financial Results 5WaferGen Reports Fourth Quarter and Full Year 2010 Financial Results 6WaferGen Reports Fourth Quarter and Full Year 2010 Financial Results 7WaferGen Reports Fourth Quarter and Full Year 2010 Financial Results 8
(Date:9/22/2014)... Fancyflyingfox.com, the well-known wedding dress manufacturer and retailer, has recently ... dresses . In addition, the company has also deiced to ... Each item in the new range is now provided with ... The company has thousands of unique special occasion outfits for ... affordable prices. Its products are brand new and made with ...
(Date:9/21/2014)... the birth of an infant prior to 37 ... that has increased over the past two decades. ... (CDC), preterm birth affects nearly 500,000 babies each year, ... While medical care has improved survival rates for preterm ... neurodevelopmental outcomes of preterm infants. , Research led by ...
(Date:9/21/2014)... UNIWIGS, one of the leading online stores of real ... a line of human hair lace wigs inspired by 6 ... people what the latest celebrity hairstyles are. , ... 4 different hairstyles to choose from: a style of yaki ... and a hot ombre red lace wig. People can go ...
(Date:9/21/2014)... authorities focus on the physical activity benefits of active ... reveals that for children, playing has no goal ... is fun, done alone or with friends, and it ... also to combat boredom, sadness, fear, or loneliness." "By ... put aside several aspects of play that are beneficial ...
(Date:9/21/2014)... peanuts are more likely to trigger an allergy to ... involving mice. , The researchers say that specific chemical ... roasting process are recognised by the body,s immune system, ... response the next time it sees any peanuts. , ... of people with peanut allergies in the Western world ...
Breaking Medicine News(10 mins):Health News:Discounted Plus Size Wedding Dresses Available At Fancyflyingfox.com 2Health News:Research evaluates neurodevelomental and medical outcomes in single family room NICU 2Health News:Research evaluates neurodevelomental and medical outcomes in single family room NICU 3Health News:UniWigs New Arrivals Just In- Human Hair Lace Wigs Inspired By Famous Celebrities 2Health News:Narrow focus on physical activity could be ruining kids' playtime 2Health News:Dry roasting could help trigger peanut allergy 2
... ... brought another family together for the holidays , ... (PRWEB) December 31, 2009 -- Celebrating the holidays under the grip of ... story evoking the true spirit of the holidays. "Before he began using drugs like ...
... ... year right , ... (PRWEB) -- Massage Envy , the nation’s largest massage therapy provider, recommends ringing in ... program. Along with resolving to eat healthier, take vitamins and exercise more frequently, incorporating ...
... a little extra incentive to kick the habit? Just ... that even after age 80, smoking continues to increase one,s ... blindness in Americans over 65. The ... January edition. "The take-home message is that it,s never ...
... , GAINESVILLE, Fla., ... the delegation at the Florida House on Capitol Hill in Washington, ... efforts to establish a gallery and learning center in Ft. Myers, ... while bridging differences and strengthening relationships. , (Photo: ...
... of the Streptococcus pneumoniae in samples that ... may predict risk of severe disease in H1N1 pandemic ... associated with higher morbidity and mortality than in other ... Immunity (CII) at the Mailman School of Public Health ...
... , , , , WOONSOCKET, ... will provide H1N1 flu vaccinations at select CVS/pharmacy ... and New York as well at MinuteClinic locations in Massachusetts ... ) , Public health officials are now encouraging everyone ...
Cached Medicine News:Health News:Mother and Son Spend Holidays Free of Drug Addiction 2Health News:Ring in a Healthy New Year with Massage Therapy in 2010 2Health News:It's never too late to quit smoking and save your vision 2Health News:Founders of the Sebastian Ferrero Foundation Join HSH Prince Albert II of Monaco in Support of the New Art of the Olympians Museum 2Health News:Founders of the Sebastian Ferrero Foundation Join HSH Prince Albert II of Monaco in Support of the New Art of the Olympians Museum 3Health News:Founders of the Sebastian Ferrero Foundation Join HSH Prince Albert II of Monaco in Support of the New Art of the Olympians Museum 4Health News:Severity of H1N1 influenza linked to presence of Streptococcus pneumoniae 2Health News:CVS/pharmacy and MinuteClinic to Provide H1N1 Vaccines in 8 New States 2Health News:CVS/pharmacy and MinuteClinic to Provide H1N1 Vaccines in 8 New States 3Health News:CVS/pharmacy and MinuteClinic to Provide H1N1 Vaccines in 8 New States 4
... closes various plastic primary and secondary tubes in ... heights and diameters can be sealed in one ... send-outs. The integration into other PVT Systems (e.g. ... and High Throughput Sorter RSD ProVolume ) ...
... MGB Alert Detection Reagents provide molecular ... PCR based assays. By using our MGB ... analysis, Nanogen is now able to provide ... nucleic acid sequences of specific organisms or ...
... for the detection of two genetic ... mutation on the Factor V (Leiden) ... the Prothrombin gene. Laboratories may use ... *Analyte Specific Reagents. Analytical ...
... the latest and most advanced fecal occult ... line. An immunochemical FOBT (iFOBT) with high ... proven to detect bleeding associated with more ... Because of its superior specificity for lower ...
Medicine Products: